262 related articles for article (PubMed ID: 34210321)
21. A Rare Case of Necrotizing Myopathy and Fibrinous and Organizing Pneumonia with Anti-EJ Antisynthetase Syndrome and SSA Antibodies.
Kashif M; Arya D; Niazi M; Khaja M
Am J Case Rep; 2017 Apr; 18():448-453. PubMed ID: 28439062
[TBL] [Abstract][Full Text] [Related]
22. Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital.
Suga T; Oiwa H; Ishida M; Iwamoto Y
Clin Rheumatol; 2022 Sep; 41(9):2803-2808. PubMed ID: 35399148
[TBL] [Abstract][Full Text] [Related]
23. Immune-mediated necrotizing myopathy (NAM) related to SARS-Cov-2 infection: a case report.
Ibrahim A; Ghazali WSW; Misyail A; Najwa L; Khan AH; Amir WM; Payus AO; Chao LW; Baharin J; Shahril NS; Yusoff SM; Aliaa W; Kee HF; Basri H
BMC Neurol; 2023 Mar; 23(1):117. PubMed ID: 36949469
[TBL] [Abstract][Full Text] [Related]
24. The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.
Cavazzana I; Fredi M; Selmi C; Tincani A; Franceschini F
Clin Rev Allergy Immunol; 2017 Feb; 52(1):88-98. PubMed ID: 26514357
[TBL] [Abstract][Full Text] [Related]
25. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
[TBL] [Abstract][Full Text] [Related]
26. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
Aggarwal R; Oddis CV; Goudeau D; Koontz D; Qi Z; Reed AM; Ascherman DP; Levesque MC
Rheumatology (Oxford); 2016 Jun; 55(6):991-9. PubMed ID: 26888854
[TBL] [Abstract][Full Text] [Related]
27. Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling.
Melki I; Devilliers H; Gitiaux C; Bondet V; Duffy D; Charuel JL; Miyara M; Bokov P; Kheniche A; Kwon T; Authier FJ; Allenbach Y; Belot A; Bodemer C; Bourrat E; Dumaine C; Fabien N; Faye A; Frémond ML; Hadchouel A; Kitabayashi N; Lepelley A; Martin-Niclos MJ; Mudumba S; Musset L; Quartier P; Rice GI; Seabra L; Uettwiller F; Uggenti C; Viel S; Rodero MP; Crow YJ; Bader-Meunier B
Rheumatology (Oxford); 2020 Aug; 59(8):1927-1937. PubMed ID: 31755959
[TBL] [Abstract][Full Text] [Related]
28. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care.
Papadopoulou C; Chew C; Wilkinson MGL; McCann L; Wedderburn LR
Nat Rev Rheumatol; 2023 Jun; 19(6):343-362. PubMed ID: 37188756
[TBL] [Abstract][Full Text] [Related]
29. Juvenile Idiopathic Inflammatory Myopathies.
Huber AM
Pediatr Clin North Am; 2018 Aug; 65(4):739-756. PubMed ID: 30031496
[TBL] [Abstract][Full Text] [Related]
30. [Focal myositis: An unknown disease].
Gallay L; Streichenberger N; Benveniste O; Allenbach Y
Rev Med Interne; 2017 Oct; 38(10):679-684. PubMed ID: 28947258
[TBL] [Abstract][Full Text] [Related]
31. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.
Rider LG; Nistala K
J Intern Med; 2016 Jul; 280(1):24-38. PubMed ID: 27028907
[TBL] [Abstract][Full Text] [Related]
32. Respiratory failure as presenting symptom of necrotizing autoimmune myopathy with anti-melanoma differentiation-associated gene 5 antibodies.
Jaeger B; de Visser M; Aronica E; van der Kooi AJ
Neuromuscul Disord; 2015 Jun; 25(6):457-60. PubMed ID: 25891278
[TBL] [Abstract][Full Text] [Related]
33. Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.
Basharat P; Christopher-Stine L
Curr Rheumatol Rep; 2015 Dec; 17(12):72. PubMed ID: 26515574
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory myopathy occurring shortly after severe acute respiratory syndrome coronavirus 2 vaccination: two case reports.
Vutipongsatorn K; Isaacs A; Farah Z
J Med Case Rep; 2022 Jan; 16(1):57. PubMed ID: 35094715
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics of patients with anti-TIF1-γ antibodies.
Masiak A; Kulczycka J; Czuszyńska Z; Zdrojewski Z
Reumatologia; 2016; 54(1):14-8. PubMed ID: 27407271
[TBL] [Abstract][Full Text] [Related]
36. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis.
Gupta L; Naveen R; Gaur P; Agarwal V; Aggarwal R
Semin Arthritis Rheum; 2021 Feb; 51(1):113-120. PubMed ID: 33360322
[TBL] [Abstract][Full Text] [Related]
37. Paraneoplastic anti-TIF1-gamma-positive dermatomyositis as expression of cervical squamous cell carcinoma recurrence.
van Erp MAJM; Slaats FMA; Emmen JMA; van Hamont D
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38262717
[TBL] [Abstract][Full Text] [Related]
38. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.
Pinal-Fernandez I; Ferrer-Fabregas B; Trallero-Araguas E; Balada E; Martínez MA; Milisenda JC; Aparicio-Español G; Labrador-Horrillo M; Garcia-Patos V; Grau-Junyent JM; Selva-O'Callaghan A
Rheumatology (Oxford); 2018 Feb; 57(2):388-396. PubMed ID: 29149307
[TBL] [Abstract][Full Text] [Related]
39. The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome.
Lu X; Peng Q; Wang G
Curr Opin Rheumatol; 2019 Nov; 31(6):643-649. PubMed ID: 31369431
[TBL] [Abstract][Full Text] [Related]
40. Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum".
Hamann PD; Cooper RG; McHugh NJ; Chinoy H
Autoimmun Rev; 2013 Oct; 12(12):1177-81. PubMed ID: 23851103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
